Long-term safety of mepolizumab for up to ∼10 years in patients with severe asthma: open-label extension study

Autor:	Ian Pavord, Robert Chan, Nicola Brown, Peter Howarth, Martyn Gilson, Robert G. Price, Jorge Maspero
Jazyk:	angličtina
Rok vydání:	2024
Předmět:	Long-term access program mepolizumab open-label extension safety severe asthma with an eosinophilic phenotype Medicine
Zdroj:	Annals of Medicine, Vol 56, Iss 1 (2024)
Druh dokumentu:	article
ISSN:	07853890 1365-2060 0785-3890
DOI:	10.1080/07853890.2024.2417184
Popis:	Objectives Long-term safety monitoring of mepolizumab is necessary to support real-world use for the treatment of severe asthma. This Long-Term Access Program assessed the safety and benefit:risk of mepolizumab in pediatric, adolescent, and adult patients with severe asthma.Materials and methods This was a multicenter, Phase IIIb safety, open-label extension study of multiple prior studies assessing mepolizumab in addition to standard of care (Aug 2015 − Aug 2022). Adults/adolescents (≥12 years of age) received mepolizumab 100 mg subcutaneously (SC) every 4 weeks until mepolizumab was commercialized. Pediatric patients (6–11 years of age) received mepolizumab 40 mg or 100 mg SC (bodyweight
Databáze:	Directory of Open Access Journals
Externí odkaz:	https://doaj.org/article/bd0898e3f87142f18fa40e8716ed1f0d Zobrazit plný text záznamu View record in DOAJ